Retatrutide 20MG

RETATRUTIDE | Triple-Agonist Metabolic Research

Exploring the Next Generation of Metabolic Science

Retatrutide is an investigational, once-weekly triple hormone receptor agonist that activates the receptors for GIP, GLP-1, and glucagon. This unique mechanism has made retatrutide an important area of research in metabolic and cardiometabolic science.

Clinical research is evaluating retatrutide in areas including body-weight regulation, glucose metabolism, cardiovascular health, sleep apnea, and other obesity-related conditions. Phase 3 trials have reported substantial changes in body weight and glycemic measures, while ongoing research continues to evaluate its overall safety and efficacy.

Research Focus

• GIP, GLP-1 & glucagon receptor signaling
• Appetite and energy-balance pathways
• Glucose and metabolic regulation
• Body-weight research
• Cardiometabolic health
• Next-generation incretin biology

Research Status: Investigational
Not currently FDA-approved

Research use only. 

Three pathways. One mission. Explore the science.